ArticleNeoplasia (New York, N.Y.)2006
In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice.
Article in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 112 citations in OpenAlex.
- Review
- Review
- Depth of Sequencing Plays a Determining Role in the Characterization of Phage Display Peptide Libraries by NGS.International journal of molecular sciences · 2023Article
- Selection of Cancer Stem Cell-Targeting Agents Using Bacteriophage Display.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Bacteriophage Capsid Modification by Genetic and Chemical Methods.Bioconjugate chemistry · 2021Review
- Article
- Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides.Biomolecules · 2020Article
- Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging.Diagnostics (Basel, Switzerland) · 2019Article
- Efficient Prostate Cancer Therapy with Tissue-Specific Homing Peptides Identified by Advanced Phage Display Technology.Molecular therapy oncolytics · 2019Article
- Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting.Advanced drug delivery reviews · 2018Review
- Phage Ligands for Identification of Mesenchymal-Like Breast Cancer Cells and Cancer-Associated Fibroblasts.Frontiers in oncology · 2018Article
- Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles.Drug delivery · 2017Review
- High-Throughput Approaches to the Development of Molecular Imaging Agents.Molecular imaging and biology · 2017Review
- Guiding nanomaterials to tumors for breast cancer precision medicine: from tumor-targeting small-molecule discovery to targeted nanodrug delivery.NPG Asia materials · 2017Article
- Characterization of In Vivo Selected Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Discovery of novel peptides targeting pro-atherogenic endothelium in disturbed flow regions -Targeted siRNA delivery to pro-atherogenic endothelium in vivo.Scientific reports · 2016Article
- Promiscuous tumor targeting phage proteins.Protein engineering, design & selection : PEDS · 2016Article
- Targeting Tumors with Small Molecule Peptides.Current cancer drug targets · 2016Review
- Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.Combinatorial chemistry & high throughput screening · 2016Article
- In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.Molecular imaging and biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
There is an increasing medical need to detect and spatially localize early and aggressive forms of prostate cancer. Affinity ligands derived from bacteriophage (phage) library screens can be developed to molecularly target prostate cancer with fluorochromes for optical imaging. Toward this goal, we used in vivo phage display and a newly described micropanning assay to select for phage that extravasate and bind human PC-3 prostate carcinoma xenografts in severe combined immune deficiency mice. One resulting phage clone (G1) displaying the peptide sequence IAGLATPGWSHWLAL was fluorescently labeled with the near-infrared fluorophore AlexaFluor 680 and was evaluated both in vitro and in vivo for its ability to bind and target PC-3 prostate carcinomas. The fluorescently labeled phage clone (G1) had a tumor-to-muscle ratio of approximately 30 in experiments. In addition, prostate tumors (PC-3) were readily detectable by optical-imaging methods. These results show proof of principle that disease-specific library-derived fluorescent probes can be rapidly developed for use in the early detection of cancers by optical means.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.